000048671 001__ 48671
000048671 005__ 20200221144341.0
000048671 0247_ $$2doi$$a10.1371/journal.pone.0150785
000048671 0248_ $$2sideral$$a94615
000048671 037__ $$aART-2016-94615
000048671 041__ $$aeng
000048671 100__ $$0(orcid)0000-0001-6845-9334$$aDe Castro-Orós, I.$$uUniversidad de Zaragoza
000048671 245__ $$aGenetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of Armolipid Plus with berberine
000048671 260__ $$c2016
000048671 5060_ $$aAccess copy available to the general public$$fUnrestricted
000048671 5203_ $$aBackground: Armolipid Plus (AP) is a nutraceutical that contains policosanol, fermented rice with red yeast, berberine, coenzyme Q10, folic acid, and astaxanthin. It has been shown to be effective in reducing plasma LDL cholesterol (LDLc) levels. In the multicenter randomized trial NCT01562080, there was large interindividual variability in the plasma LDLc response to AP supplementation. We hypothesized that the variability in LDLc response to AP supplementation may be linked to LDLR and PCSK9 polymorphisms. Material and Methods: We sequenced the LDLR 30 and 50 untranslated regions (UTR) and the PCSK9 50 UTR of 102 participants with moderate hypercholesterolemia in trial NCT01562080. In this trial, 50 individuals were treated with AP supplementation and the rest with placebo. Results: Multiple linear regression analysis, using the response of LDLc levels to AP as the dependent variable, revealed that polymorphisms rs2149041 (c.-3383C>G) in the PCSK9 50 UTR and rs14158 (c.*52G>A) in the LDLR 30 UTR explained 14.1%and 6.4%, respectively, of the variability after adjusting for gender, age, and BMI of individuals. Combining polymorphisms rs2149041 and rs14158 explained 20.5%of this variability (p A, c.*504G>A, and c. *773A>G, and two at the 50 UTR region of PCSK9, c.-3383C>G and c.-2063A>G, were associated with response to AP. These results could explain the variability observed in the response to berberine among people with moderate hypercholesterolemia, and they may be useful in identifying patients who could potentially benefit from supplementation with AP.
000048671 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI12-01703
000048671 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000048671 590__ $$a2.806$$b2016
000048671 591__ $$aMULTIDISCIPLINARY SCIENCES$$b15 / 63 = 0.238$$c2016$$dQ1$$eT1
000048671 592__ $$a1.236$$b2016
000048671 593__ $$aAgricultural and Biological Sciences (miscellaneous)$$c2016$$dQ1
000048671 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000048671 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2016$$dQ1
000048671 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000048671 700__ $$aSolà, R.
000048671 700__ $$aValls, R.M.
000048671 700__ $$aBrea, A.
000048671 700__ $$0(orcid)0000-0001-5956-4319$$aMozas, P.$$uUniversidad de Zaragoza
000048671 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, J.$$uUniversidad de Zaragoza
000048671 700__ $$0(orcid)0000-0001-8807-9187$$aPocoví, M.$$uUniversidad de Zaragoza
000048671 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000048671 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000048671 773__ $$g11, 3 (2016), 0150785 [9 p.]$$pPLoS One$$tPloS one$$x1932-6203
000048671 8564_ $$s271651$$uhttps://zaguan.unizar.es/record/48671/files/texto_completo.pdf$$yVersión publicada
000048671 8564_ $$s94492$$uhttps://zaguan.unizar.es/record/48671/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000048671 909CO $$ooai:zaguan.unizar.es:48671$$particulos$$pdriver
000048671 951__ $$a2020-02-21-13:50:27
000048671 980__ $$aARTICLE